Mineralys Therapeutics, Inc. (MLYS)
NASDAQ · Healthcare
$26.71-1.40%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.78B
- P/E ratio
- —
- EPS
- —
- Volume
- 481,487
- 52-week high
- —
- 52-week low
- —
- Open
- $27.15
- Day high
- $27.17
- Day low
- $26.46
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$154.65M | -$2.29 |
| 2024 | — | -$177.81M | -$3.66 |
| 2023 | — | -$71.9M | -$1.99 |
| 2022 | — | -$29.8M | -$5.77 |
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
- CEO
- Jon Congleton
- Employees
- 76
- Country
- US
- IPO date
- Feb 10, 2023
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Mineralys Therapeutics, Inc.'s stock price today?
- MLYS is trading at $26.71 as of Jul 20, 2026.
- What is Mineralys Therapeutics, Inc.'s market cap?
- Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of $1.78B.
- Does Mineralys Therapeutics, Inc. pay a dividend?
- Mineralys Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Mineralys Therapeutics, Inc. in?
- Mineralys Therapeutics, Inc. operates in the Healthcare sector.